Unibest
← Back to patent-cliff list

Budesonide (Shire)

Tier C — Watch / trade

Budesonide (Shire)

Verus Pharmaceuticals
Originator
2024
First approval
-
Expiry (public)
$0.06B ▲
Peak sales
Small molecule
Type

Targets:GR

Brand:Eohilia

Indications (approved):Eosinophilic oesophagitis

Regional status

US
Approved
2024-02-09
EU
-
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 5 · Total yield /
Budesonide51333-22-3Budesonide-00137413-91-5Budesonide-00277017-20-0Budesonide-00391160-89-3Budesonide-00486401-80-1Budesonide-00513951-70-7Budesonide-006123-72-8API · Budesonide (Shire)
CodeCAS No.Intermediate
Budesonide51333-22-3-
Budesonide-00137413-91-52-((8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
Budesonide-00277017-20-02-((8S,10S,13S,14S,16R,17S)-16,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
Budesonide-00391160-89-32-((8S,9R,10S,11S,13S,14S,16R,17S)-9-bromo-11,16,17-trihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
Budesonide-00486401-80-12-oxo-2-((8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate
Budesonide-00513951-70-7(8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
Budesonide-006123-72-8butyraldehyde

Frequently asked questions

What are the approved indications of Budesonide (Shire)?

Approved indications include: Eosinophilic oesophagitis.

When does the Budesonide (Shire) patent expire?

No public expiry year is available for Budesonide (Shire) yet; this page updates once verified.

How many synthesis routes are recorded for Budesonide (Shire)?

1 synthesis routes are recorded; the shortest is 5 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Budesonide (Shire) intermediates?

All intermediates in Budesonide (Shire) routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Budesonide (Shire) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29